Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CEA-C007 | Human | ClinMax™Human Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) Quantitative ELISA Kit | |||
CRS-A013 | Human | Human Macrophage Colony Stimulating Factor 2(GM-CSF) ELISA Kit | |||
GMF-H8214 | Human | Biotinylated Human GM-CSF, epitope tag free, ultra sensitivity (primary amine labeling) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
GMF-H4214 | Human | ActiveMax® Human GM-CSF Protein, Tag Free | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Loaded Biotinylated Human GM-CSF, epitope tag free, primary amine labeling (Cat. No. GMF-H8214) on SA Biosensor, can bind Human GM-CSF R alpha, His Tag (SPR verified) (Cat. No. GRA-H52H7) with an affinity constant of 23.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Otilimab | MOR-103; MOR-04357; GSK-3196165; GSK-165 | Phase 3 Clinical | University Of Melbourne | Arthritis, Rheumatoid; Multiple Sclerosis; Severe Acute Respiratory Syndrome; Glycogen Storage Disease Type II; Osteoarthritis | Details |
BT-001 | BT-001 | Phase 2 Clinical | Transgene | Solid tumours; Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma | Details |
PBI-1402 | PBI-1402 | Phase 2 Clinical | Prometic Life Sciences | Anemia | Details |
PD-360324 | PD-360324; PD-0360324 | Phase 2 Clinical | Pfizer Pharmaceuticals Ltd (China) | Neoplasms; Lupus Erythematosus, Cutaneous; Sarcoidosis, Pulmonary | Details |
Plonmarlimab | TJ-003234RAR101; TJM-2; TJ-003234 | Phase 3 Clinical | I-Mab Biopharma Co Ltd | Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid | Details |
Gimsilumab | MORAb-022; KIN-1901 | Phase 2 Clinical | Morphotek | Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Nasopharyngeal Neoplasms; Rheumatic Diseases; Inflammation | Details |
Pexastimogene devacirepvec | TG-6006; JX-594 | Phase 3 Clinical | Sillajen, Regeneron Pharmaceuticals Inc, National Cancer Institute, Samsung Medical Center & Samsung Electronics Devices Llc | Liver Neoplasms; Rhabdomyosarcoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Wilms Tumor; Neuroblastoma; Sarcoma, Ewing; Colorectal Neoplasms; Lung Neoplasms; Lymphoma; Carcinoma, Hepatocellular; Melanoma | Details |
Bi-shRNAfurin and GMCSF augmented autologous tumor cell immunotherapy (Gradalis/Mary Crowley) | IND-14205 | Phase 3 Clinical | Gradalis | Ovarian Neoplasms; Liver Neoplasms; Colonic Neoplasms; Sarcoma, Ewing; Breast Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Uterine Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Namilumab | MT-203; AMG-203; IZN-101 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd, Amgen Inc | Spondylitis, Ankylosing; Arthritis, Rheumatoid; Psoriasis | Details |
Vusolimogene oderparepvec | RP-1 | Phase 2 Clinical | Replimune | Skin Melanoma; Carcinoma, Merkel Cell; Skin Neoplasms; Basal Cell Nevus Syndrome; Microsatellite Instability; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
SAR-441000 | SAR441000; SAR-441000; BNT-131 | Phase 1 Clinical | Biontech Se, Sanofi | Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.